Published in Circulation on September 27, 2004
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev (2008) 3.51
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2005) 1.76
Chemical probes of endocannabinoid metabolism. Pharmacol Rev (2013) 1.68
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2007) 1.65
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol (2007) 1.39
Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2007) 1.34
Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther (2007) 1.33
Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol (2007) 1.25
Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes (2008) 1.25
The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol (2009) 1.24
Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology (2005) 1.23
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol (2007) 1.22
Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov (2009) 1.22
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res (2009) 1.22
Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol (2005) 1.14
Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol (2010) 1.10
Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension (2008) 1.07
Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol (2006) 1.07
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol (2010) 1.04
The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels. J Pharmacol Exp Ther (2008) 1.03
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol (2007) 1.01
Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? Br J Pharmacol (2012) 1.00
Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol (2007) 1.00
The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J Med Chem (2008) 0.97
Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol (2007) 0.96
Endocannabinoids and the heart. J Cardiovasc Pharmacol (2009) 0.94
The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol (2009) 0.94
Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. ChemMedChem (2009) 0.93
Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol (2007) 0.92
Differential endocannabinoid regulation of baroreflex-evoked sympathoinhibition in normotensive versus hypertensive rats. Auton Neurosci (2009) 0.88
Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder. Psychopharmacology (Berl) (2009) 0.88
Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. Br J Pharmacol (2009) 0.88
Survival, exercise capacity, and left ventricular remodeling in a rat model of chronic mitral regurgitation: serial echocardiography and pressure-volume analysis. Korean Circ J (2011) 0.87
An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl) (2009) 0.87
Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. J Biol Chem (2012) 0.85
Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats. PLoS One (2013) 0.84
Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol Res (2009) 0.84
Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction. Proc Natl Acad Sci U S A (2013) 0.83
Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol Res (2014) 0.83
Effects of chronic nitric oxide synthase inhibition on the cardiovascular responses to cannabinoids in vivo and in vitro. Br J Pharmacol (2007) 0.83
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol (2006) 0.83
Impairment of insulin-stimulated Akt/GLUT4 signaling is associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic rats. J Biomed Sci (2009) 0.82
Electrophysiological effects of anandamide on rat myocardium. Br J Pharmacol (2009) 0.82
Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol (2012) 0.82
Time-dependent vascular effects of Endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARγ). PPAR Res (2009) 0.82
CB1 cannabinoid receptor inhibition: promising approach for heart failure? Congest Heart Fail (2008) 0.82
Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. Eur J Pharmacol (2009) 0.82
Cardiorespiratory anomalies in mice lacking CB1 cannabinoid receptors. PLoS One (2014) 0.81
Cirrhotic cardiomyopathy: an endocannabinoid connection? Br J Pharmacol (2005) 0.81
Serum contents of endocannabinoids are correlated with blood pressure in depressed women. Lipids Health Dis (2012) 0.80
Involvement of central beta2-adrenergic, NMDA and thromboxane A2 receptors in the pressor effect of anandamide in rats. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.80
Circulating endocannabinoid concentrations during orthostatic stress. Clin Auton Res (2009) 0.80
Expression of the endocannabinoid receptors in human fascial tissue. Eur J Histochem (2016) 0.80
Endocannabinoids in cerebrovascular regulation. Am J Physiol Heart Circ Physiol (2016) 0.79
Mechanisms of endothelial dysfunction in obesity-associated hypertension. Braz J Med Biol Res (2012) 0.79
A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats. Br J Pharmacol (2010) 0.78
Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats. Physiol Rep (2014) 0.78
Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. J Pharm Bioallied Sci (2011) 0.77
Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol (2008) 0.76
Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. PLoS One (2013) 0.76
Alterations in the Medullary Endocannabinoid System Contribute to Age-related Impairment of Baroreflex Sensitivity. J Cardiovasc Pharmacol (2015) 0.76
Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats. Br J Pharmacol (2017) 0.75
Use of pressure-volume conductance catheters in real-time cardiovascular experimentation. Heart Lung Circ (2014) 0.75
Components of the cannabinoid system in the dorsal periaqueductal gray are related to resting heart rate. Am J Physiol Regul Integr Comp Physiol (2016) 0.75
Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice. J Cardiol Ther (2015) 0.75
The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo. Metabolomics (2016) 0.75
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 10.05
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension (2002) 3.66
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation (2003) 2.56
A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 2.52
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A (2003) 2.21
Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol (1999) 2.12
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol (2003) 1.95
Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest (1997) 1.95
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension (1997) 1.75
Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol (1996) 1.75
Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol (1995) 1.72
Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol (2004) 1.51
High blood pressure, other risk factors and longevity: the insurance viewpoint. Am J Med (1973) 1.49
Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol (2003) 1.43
Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol (2001) 1.42
Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol (2002) 1.41
Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol (1974) 1.40
Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol (2003) 1.37
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol (2002) 1.36
Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol (2002) 1.32
Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids (2002) 1.30
Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension (2002) 1.28
Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension (2003) 1.20
Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther (1975) 1.12
Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol (1997) 1.11
Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension (2000) 1.06
Dose-dependent activation of antiapoptotic and proapoptotic pathways by ethanol treatment in human vascular endothelial cells: differential involvement of adenosine. J Biol Chem (2002) 0.98
CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice. Hypertension (2002) 0.97
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol (2004) 0.96
Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Relationship to adenylate cyclase inhibition. Biochem J (1992) 0.93
beta-endorphin acting on the brainstem is involved in the antihypertensive action of clonidine and alpha-methyldopa in rats. Circ Res (1983) 0.86
Antihypertensive effects of delta9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther (1978) 0.83
Prevalence of diabetes among men and women in China. N Engl J Med (2010) 19.98
Reach and grasp by people with tetraplegia using a neurally controlled robotic arm. Nature (2012) 7.87
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (2013) 6.98
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A (2008) 6.53
Augmented Wnt signaling in a mammalian model of accelerated aging. Science (2007) 5.62
A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A (2008) 5.48
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Regulation of homologous recombination in eukaryotes. Annu Rev Genet (2010) 4.33
The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron (2006) 4.12
miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer (2008) 4.09
Superoxide flashes in single mitochondria. Cell (2008) 4.08
The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol (2013) 3.39
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest (2008) 3.13
MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet (2010) 3.12
Phospholipase C in living cells: activation, inhibition, Ca2+ requirement, and regulation of M current. J Gen Physiol (2005) 2.98
Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology (2004) 2.93
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med (2008) 2.91
Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab (2008) 2.91
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc (2007) 2.84
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci (2003) 2.84
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J (2011) 2.57
Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun (2007) 2.51
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
Minireview: GNAS: normal and abnormal functions. Endocrinology (2004) 2.50
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood (2010) 2.48
Etiology of diarrhea in Bangladeshi infants in the first year of life analyzed using molecular methods. J Infect Dis (2013) 2.43
GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A (2008) 2.42
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell (2009) 2.41
Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest (2002) 2.40
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci (2010) 2.37
Experimental febrile seizures are precipitated by a hyperthermia-induced respiratory alkalosis. Nat Med (2006) 2.34
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Light-sensitive neurons and channels mediate phototaxis in C. elegans. Nat Neurosci (2008) 2.32
Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci (2005) 2.32
Genome-wide association study dissects the genetic architecture of oil biosynthesis in maize kernels. Nat Genet (2012) 2.25
Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science (2007) 2.21
Genetic mechanisms of hepatocarcinogenesis. Oncogene (2002) 2.21
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A (2003) 2.21
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med (2013) 2.19
Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol (2009) 2.17
Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol Appl Pharmacol (2003) 2.16
Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods (2013) 2.14
Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. J Physiol (2004) 2.09
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A (2006) 2.08
Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci (2004) 2.08
Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol (2005) 2.06
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Comparison of one-level minimally invasive and open transforaminal lumbar interbody fusion in degenerative and isthmic spondylolisthesis grades 1 and 2. Eur Spine J (2010) 2.02
Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology (2012) 2.01
Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression. Blood (2008) 2.01
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology (2003) 2.00
Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol (2005) 1.98
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol (2003) 1.95